PubMed Health⌕ Search

Biomedical subjects

S Ohtake

Publications and source records attributed to S Ohtake.

At least 163 records · Page 9Linked to original sources
PubMed1986

[Clinical study of non-Hodgkin's lymphoma--results of the Kanazawa University-Kurume University Cooperative Study on Malignant Lymphomas].

Ninety-two patients with previously untreated non-Hodgkin's lymphoma (NHL) were studied multidisciplinarily. The high incidence of NHL in elderly men (older than 60 years) was confirmed. With regard to the initial site, 51 patients (55.5%) were affected in the nodal region while other patients were affected in the extranodal or Waldeyer's ring region. Eighty-two patients (89.1%) were diagnosed as having diffuse lymphoma, and 47 of these patients were further classified into large cell type (LSG classification). Surface marker analysis revealed that the incidence of B cell-type NHL was twice as high as that of T cell-type NHL. All patients were entered into a randomized trial of radiotherapy and/or combination chemotherapies (ACOP, ACOP-E and AclBEP regimens) according to clinical stage. More than 90% of the patients with early-stage NHL achieved complete remission (CR), and the CR rate for patients with advanced-stage disease was about 50%. All patients with CS I NHL are still alive at 27 months after diagnosis, and the survival rate of patients with CS II NHL at 35 months after diagnosis is 80%. However, the median survival time of patients with advanced-stage disease was estimated to be 16 months.

Adult↗
PubMed1986

[ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].

Nineteen patients with refractory non-Hodgkin's lymphoma were treated with a combination of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (150-200 mg/m2), aclacinomycin (15 mg/m2), etoposide (70 mg/m2 i.v. or 100 mg/m2 p.o) and prednisolone (20 mg/m2) (ABEP regimen). Patients who achieved complete remission (CR) received 10 courses of consolidation therapy with ACOP-E chemotherapy (adriamycin, cyclophosphamide, vincristine, prednisolone and etoposide). Seven patients achieved CR and three partial remission. Twelve patients with fresh non-Hodgkin's lymphoma stage IV were treated with ABEP regimen. CR was obtained in eight patients (66.7%). The median duration of CR was 11+ alpha months. Hematological toxicity was a dose-limiting factor but this was manageable.

Aclarubicin↗
PubMed1985

[The role of radiotherapy in the treatment of Hodgkin's disease].

Twenty-two patients with Hodgkin's disease were treated at Kanazawa University between 1975 and 1982. Patients in stage I or II were treated with radiotherapy. Those in stage III or IV underwent combination chemotherapy (MOPP) with or without radiotherapy. Twenty patients have achieved a complete remission (90.9%). The 10-year survival rate of all patients is 90%: 100% for patients in stage I or II and 73% for patients in stage III or IV. Thus, radiotherapy can be recommended as a primary treatment for patients in stage I or II while MOPP with radiotherapy could be effective for those in stage III or IV.

Adolescent↗